메뉴 건너뛰기




Volumn 11, Issue 12, 2010, Pages 2011-2026

Improving blood pressure control rates by optimizing combination antihypertensive therapy

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Calcium channel blockers; Combination therapy; Diuretics; Hypertension; Triple therapy

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; LISINOPRIL; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL; DRUG COMBINATION;

EID: 77954782157     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.500614     Document Type: Review
Times cited : (15)

References (83)
  • 1
    • 37149026076 scopus 로고    scopus 로고
    • Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004
    • Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007;167:2431-2436
    • (2007) Arch Intern Med , vol.167 , pp. 2431-2436
    • Wong, N.D.1    Lopez, V.A.2    L'Italien, G.3
  • 2
    • 0025959101 scopus 로고
    • An updated coronary risk profile. A statement for health professionals
    • Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362
    • (1991) Circulation , vol.83 , pp. 356-362
    • Anderson, K.M.1    Wilson, P.W.2    Odell, P.M.3    Kannel, W.B.4
  • 3
    • 0035522330 scopus 로고    scopus 로고
    • Impact of high-normal blood pressure on the risk of cardiovascular disease
    • Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-1297
    • (2001) N Engl J Med , vol.345 , pp. 1291-1297
    • Vasan, R.S.1    Larson, M.G.2    Leip, E.P.3
  • 4
    • 0037079309 scopus 로고    scopus 로고
    • Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies
    • Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913
    • (2002) Lancet , vol.360 , pp. 1903-1913
    • Lewington, S.1    Clarke, R.2    Qizilbash, N.3
  • 5
    • 0242654867 scopus 로고    scopus 로고
    • Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
    • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535
    • (2003) Lancet , vol.362 , pp. 1527-1535
    • Turnbull, F.1
  • 6
    • 33746797303 scopus 로고    scopus 로고
    • Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis
    • Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006;48:833-838
    • (2006) J Am Coll Cardiol , vol.48 , pp. 833-838
    • Sipahi, I.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 7
    • 33847633400 scopus 로고    scopus 로고
    • Prevalence awareness treatment and control of hypertension among United States adults 1999-2004
    • Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
    • (2007) Hypertension , vol.49 , pp. 69-75
    • Ong, K.L.1    Cheung, B.M.2    Man, Y.B.3
  • 8
    • 69349103215 scopus 로고    scopus 로고
    • The hypertension paradox: More uncontrolled disease despite improved therapy
    • Shattuck Lecture
    • Chobanian AV. Shattuck Lecture. The hypertension paradox: more uncontrolled disease despite improved therapy. N Engl J Med 2009;361:878-887
    • (2009) N Engl J Med , vol.361 , pp. 878-887
    • Chobanian, A.V.1
  • 9
    • 73649132652 scopus 로고    scopus 로고
    • Reappraisal of European guidelines on hypertension management: A European Society of hypertension task force document
    • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-347
    • (2009) Blood Press , vol.18 , pp. 308-347
    • Mancia, G.1    Laurent, S.2    Agabiti-Rosei, E.3
  • 10
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
    • (2010) N Engl J Med , vol.362 , pp. 1575-1585
    • Cushman, W.C.1    Evans, G.W.2    Byington, R.P.3
  • 11
    • 0347423198 scopus 로고    scopus 로고
    • Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
    • Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-1252
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 13
    • 44149120305 scopus 로고    scopus 로고
    • It's time to overcome clinical inertia
    • Phillips LS, Twombly JG. It's time to overcome clinical inertia. Ann Intern Med 2008;148:783-785
    • (2008) Ann Intern Med , vol.148 , pp. 783-785
    • Phillips, L.S.1    Twombly, J.G.2
  • 14
    • 33644979283 scopus 로고    scopus 로고
    • Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals
    • Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006;47:345-351
    • (2006) Hypertension , vol.47 , pp. 345-351
    • Okonofua, E.C.1    Simpson, K.N.2    Jesri, A.3
  • 15
    • 57349138291 scopus 로고    scopus 로고
    • Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
    • (2008) N Engl J Med , vol.359 , pp. 2417-2428
    • Jamerson, K.1    Weber, M.A.2    Bakris, G.L.3
  • 16
    • 58949098039 scopus 로고    scopus 로고
    • Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    • Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2008;10:751-760
    • (2008) J Clin Hypertens (Greenwich) , vol.10 , pp. 751-760
    • Cushman, W.C.1    Ford, C.E.2    Einhorn, P.T.3
  • 17
    • 33745987893 scopus 로고    scopus 로고
    • Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial
    • Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-79
    • (2006) Hypertension , vol.48 , pp. 73-79
    • Ridker, P.M.1    Danielson, E.2    Rifai, N.3    Glynn, R.J.4
  • 18
    • 47249088609 scopus 로고    scopus 로고
    • Efficacy and safety of amlodipine/ valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: A randomized, double-blind, multicenter study: The EX-EFFeCTS Study
    • Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/ valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008;2:294-302
    • (2008) J Am Soc Hypertens , vol.2 , pp. 294-302
    • Destro, M.1    Luckow, A.2    Samson, M.3
  • 19
    • 67649449128 scopus 로고    scopus 로고
    • Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study
    • Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-489
    • (2009) J Hum Hypertens , vol.23 , pp. 479-489
    • Flack, J.M.1    Calhoun, D.A.2    Satlin, L.3
  • 20
    • 4644242120 scopus 로고    scopus 로고
    • The burden of adult hypertension in the United States 1999 to 2000: A rising tide
    • Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404
    • (2004) Hypertension , vol.44 , pp. 398-404
    • Fields, L.E.1    Burt, V.L.2    Cutler, J.A.3
  • 21
    • 0023727613 scopus 로고
    • Age and blood pressure changes. A 20-year follow-up study in nuns in a secluded order
    • Timio M, Verdecchia P, Venanzi S, et al. Age and blood pressure changes. A 20-year follow-up study in nuns in a secluded order. Hypertension 1988;12:457-461
    • (1988) Hypertension , vol.12 , pp. 457-461
    • Timio, M.1    Verdecchia, P.2    Venanzi, S.3
  • 22
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 23
    • 2942695964 scopus 로고    scopus 로고
    • Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
    • Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051
    • (2004) Lancet , vol.363 , pp. 2049-2051
    • Weber, M.A.1    Julius, S.2    Kjeldsen, S.E.3
  • 25
    • 11144356621 scopus 로고    scopus 로고
    • Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial
    • Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847-857
    • (2004) J Hypertens , vol.22 , pp. 847-857
    • Staessen, J.A.1    Thijisq, L.2    Fagard, R.3
  • 26
    • 58149399241 scopus 로고    scopus 로고
    • Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?
    • Nasser SA, Lai Z, O'Connor S, et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008;10:398-404
    • (2008) Curr Hypertens Rep , vol.10 , pp. 398-404
    • Nasser, S.A.1    Lai, Z.2    O'Connor, S.3
  • 27
    • 18244395882 scopus 로고    scopus 로고
    • Early and aggressive treatment of complex hypertension
    • Mugo MN, Sowers JR. Early and aggressive treatment of complex hypertension. J Clin Hypertens (Greenwich) 2005;7:8-10
    • (2005) J Clin Hypertens (Greenwich) , vol.7 , pp. 8-10
    • Mugo, M.N.1    Sowers, J.R.2
  • 28
    • 0346102472 scopus 로고    scopus 로고
    • Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchangeability
    • Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
    • (2004) Hypertension , vol.43 , pp. 4-9
    • Carter, B.L.1    Ernst, M.E.2    Cohen, J.D.3
  • 29
    • 52449097821 scopus 로고    scopus 로고
    • Should chlorthalidone be the diuretic of choice for antihypertensive therapy?
    • Taler SJ. Should chlorthalidone be the diuretic of choice for antihypertensive therapy? Curr Hypertens Rep 2008;10:293-297
    • (2008) Curr Hypertens Rep , vol.10 , pp. 293-297
    • Taler, S.J.1
  • 30
    • 33644981542 scopus 로고    scopus 로고
    • Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure
    • Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358
    • (2006) Hypertension , vol.47 , pp. 352-358
    • Ernst, M.E.1    Carter, B.L.2    Goerdt, C.J.3
  • 31
    • 58149457772 scopus 로고    scopus 로고
    • All thiazide-like diuretics are not chlorthalidone: Putting the ACCOMPLISH study into perspective
    • Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich) 2009;11:5-10
    • (2009) J Clin Hypertens (Greenwich) , vol.11 , pp. 5-10
    • Ernst, M.E.1    Carter, B.L.2    Basile, J.N.3
  • 33
    • 77649091668 scopus 로고    scopus 로고
    • American Association of clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus
    • Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
    • (2007) Endocr Pract , vol.13 , Issue.SUPPL. 1 , pp. 1-68
    • Rodbard, H.W.1    Blonde, L.2    Braithwaite, S.S.3
  • 34
    • 63849238764 scopus 로고    scopus 로고
    • Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists
    • Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-946
    • (2008) Endocr Pract , vol.14 , pp. 933-946
    • Garber, A.J.1    Handelsman, Y.2    Einhorn, D.3
  • 35
    • 59349091844 scopus 로고    scopus 로고
    • Risk factor assessment for new onset diabetes: Literature review
    • Bakris G, Stockert J, Molitch M, et al. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-187
    • (2009) Diabetes Obes Metab , vol.11 , pp. 177-187
    • Bakris, G.1    Stockert, J.2    Molitch, M.3
  • 36
    • 38949084591 scopus 로고    scopus 로고
    • Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31:353-360
    • (2008) Diabetes Care , vol.31 , pp. 353-360
    • Black, H.R.1    Davis, B.2    Barzilay, J.3
  • 37
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
    • Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3
  • 38
    • 48649106720 scopus 로고    scopus 로고
    • Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication
    • Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-988
    • (2008) Diabetes Care , vol.31 , pp. 982-988
    • Gupta, A.K.1    Dahlof, B.2    Dobson, J.3
  • 39
    • 7744237066 scopus 로고    scopus 로고
    • Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
    • Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-2236
    • (2004) JAMA , vol.292 , pp. 2227-2236
    • Bakris, G.L.1    Fonseca, V.2    Katholi, R.E.3
  • 40
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3
  • 41
    • 57849090023 scopus 로고    scopus 로고
    • Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome
    • Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10:894-903
    • (2008) J Clin Hypertens (Greenwich) , vol.10 , pp. 894-903
    • Zappe, D.H.1    Sowers, J.R.2    Hsueh, W.A.3
  • 42
    • 36248942124 scopus 로고    scopus 로고
    • Epidemiology and unmet need in hypertension
    • Flack JM. Epidemiology and unmet need in hypertension. J Manag Care Pharm 2007;13(8 Suppl S-b):S2-8
    • (2007) J Manag Care Pharm , vol.13 , Issue.8 SUPPL. S-B
    • Flack, J.M.1
  • 43
    • 55249099160 scopus 로고    scopus 로고
    • Improving blood pressure control: Increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial
    • White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich) 2008;10:450-458
    • (2008) J Clin Hypertens (Greenwich) , vol.10 , pp. 450-458
    • White, W.B.1    Calhoun, D.A.2    Samuel, R.3
  • 45
    • 7744231805 scopus 로고    scopus 로고
    • Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study:A randomized controlled trial
    • Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study:a randomized controlled trial. JAMA 2004;292:2217-2225
    • (2004) JAMA , vol.292 , pp. 2217-2225
    • Nissen, S.E.1    Tuzcu, E.M.2    Libby, P.3
  • 46
    • 34250005878 scopus 로고    scopus 로고
    • Nitric oxide mechanisms in the pathogenesis of global risk
    • Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich) 2006;8(8 Suppl 2):31-38
    • (2006) J Clin Hypertens (Greenwich) , vol.8 , Issue.8 SUPPL. 2 , pp. 31-38
    • Mason, R.P.1
  • 47
    • 52449127123 scopus 로고    scopus 로고
    • Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease
    • Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens 2008;21:1076-1085
    • (2008) Am J Hypertens , vol.21 , pp. 1076-1085
    • Mizuno, Y.1    Jacob, R.F.2    Mason, R.P.3
  • 48
    • 34447109035 scopus 로고    scopus 로고
    • Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
    • Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580
    • (2007) Clin Ther , vol.29 , pp. 563-580
    • Philipp, T.1    Smith, T.R.2    Glazer, R.3
  • 49
    • 33747382766 scopus 로고    scopus 로고
    • Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    • Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006;48:374-384
    • (2006) Hypertension , vol.48 , pp. 374-384
    • Leenen, F.H.1    Nwachuku, C.E.2    Black, H.R.3
  • 50
    • 0037429639 scopus 로고    scopus 로고
    • Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    • Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-541
    • (2003) Arch Intern Med , vol.163 , pp. 525-541
    • Douglas, J.G.1    Bakris, G.L.2    Epstein, M.3
  • 51
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
    • (2001) N Engl J Med , vol.345 , pp. 861-869
    • Brenner, B.M.1    Cooper, M.E.2    De Zeeuw, D.3
  • 52
    • 67649855145 scopus 로고    scopus 로고
    • Triple fixed-dose combination therapy: Back to the past
    • Black HR. Triple fixed-dose combination therapy: back to the past. Hypertension 2009;54:19-22
    • (2009) Hypertension , vol.54 , pp. 19-22
    • Black, H.R.1
  • 53
    • 64849106873 scopus 로고    scopus 로고
    • A simplified approach to the treatment of uncomplicated hypertension: A cluster randomized, controlled trial
    • Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-653
    • (2009) Hypertension , vol.53 , pp. 646-653
    • Feldman, R.D.1    Zou, G.Y.2    Vandervoort, M.K.3
  • 54
    • 64849103457 scopus 로고    scopus 로고
    • Fixed-dose combinations and hypertension control in community-based practices: Application of the 'keep-it-simple' principle
    • Egan BM. Fixed-dose combinations and hypertension control in community-based practices: application of the 'keep-it-simple' principle. Hypertension 2009;53:598-599
    • (2009) Hypertension , vol.53 , pp. 598-599
    • Egan, B.M.1
  • 55
    • 43549108344 scopus 로고    scopus 로고
    • Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after Single Therapy (EX-FAST) study
    • Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008;10:185-194
    • (2008) J Clin Hypertens (Greenwich) , vol.10 , pp. 185-194
    • Allemann, Y.1    Fraile, B.2    Lambert, M.3
  • 56
    • 84925560559 scopus 로고    scopus 로고
    • Efficacy of amlodipine/valsartan/ hydrochlorothiazide triple combination in patients whose blood pressure was not controlled with dual combinations: The PROMPT extension study
    • Presented at 6 - 9 May 2009; San Francisco, CA
    • Zappe DH, Crikelair N, Papst CC, et al. Efficacy of amlodipine/valsartan/ hydrochlorothiazide triple combination in patients whose blood pressure was not controlled with dual combinations: the PROMPT extension study. Presented at: American Society of Hypertension, 24th Annual Scientific Meeting and Exposition; 6 - 9 May 2009; San Francisco, CA
    • American Society of Hypertension, 24th Annual Scientific Meeting and Exposition
    • Zappe, D.H.1    Crikelair, N.2    Papst, C.C.3
  • 57
    • 3442882539 scopus 로고    scopus 로고
    • Use of an olmesartan medoxomil-based treatment algorithm for hypertension control
    • Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168-174
    • (2004) J Clin Hypertens (Greenwich) , vol.6 , pp. 168-174
    • Neutel, J.M.1    Smith, D.H.2    Weber, M.A.3
  • 58
    • 33645089450 scopus 로고    scopus 로고
    • Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension
    • Neutel JM, Smith DH, Silfani TN, et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006;20:255-262
    • (2006) J Hum Hypertens , vol.20 , pp. 255-262
    • Neutel, J.M.1    Smith, D.H.2    Silfani, T.N.3
  • 59
    • 55949102080 scopus 로고    scopus 로고
    • Based treatment algorithm for essencial hypertension with olmesartan medoxomil
    • Gomes MA, Feitosa AD, Oigman W, et al. Based treatment algorithm for essencial hypertension with olmesartan medoxomil. Arq Bras Cardiol 2008;91:168-193
    • (2008) Arq Bras Cardiol , vol.91 , pp. 168-193
    • Gomes, M.A.1    Feitosa, A.D.2    Oigman, W.3
  • 60
    • 67549119235 scopus 로고    scopus 로고
    • Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study
    • Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009;29:381-391
    • (2009) Clin Drug Investig , vol.29 , pp. 381-391
    • Volpe, M.1    Miele, C.2    Haag, U.3
  • 61
    • 78649326084 scopus 로고    scopus 로고
    • Long-term efficacy of a combination of amlodipine and olmesartan medoxomil+/-hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: A substudy of the COACH trial
    • [Epub ahead of print]
    • Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil+/-hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens March 4, 2010. [Epub ahead of print]
    • (2010) J Hum Hypertens March , vol.4
    • Oparil, S.1    Chrysant, S.G.2    Melino, M.3
  • 62
    • 70349973807 scopus 로고    scopus 로고
    • Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
    • Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009;11:475-482
    • (2009) J Clin Hypertens (Greenwich) , vol.11 , pp. 475-482
    • Chrysant, S.G.1    Oparil, S.2    Melino, M.3
  • 63
    • 67649848168 scopus 로고    scopus 로고
    • Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial
    • Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-39
    • (2009) Hypertension , vol.54 , pp. 32-39
    • Calhoun, D.A.1    Lacourciere, Y.2    Chiang, Y.T.3    Glazer, R.D.4
  • 64
    • 84925567020 scopus 로고    scopus 로고
    • Effect of age, gender, race and ethnicity on efficacy of amlodipine/valsartan/ hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension
    • Presented at 6 - 9 May 2009; San Francisco, CA
    • Calhoun D, Glazer R, Yen J, et al. Effect of age, gender, race and ethnicity on efficacy of amlodipine/valsartan/ hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension. Presented at: American Society of Hypertension, 24th Annual Scientific Meeting and Exposition; 6 - 9 May 2009; San Francisco, CA
    • American Society of Hypertension, 24th Annual Scientific Meeting and Exposition
    • Calhoun, D.1    Glazer, R.2    Yen, J.3
  • 65
    • 84925567019 scopus 로고    scopus 로고
    • Effect of baseline systolic blood pressure on response to triple combination amlodipine/valsartan/ hydrochlorothiazide in patients with moderate-to-severe hypertension
    • Presented at 6 - 9 May 2009; San Francisco, CA
    • Lacourciere Y, Glazer R, Crikelair N, et al. Effect of baseline systolic blood pressure on response to triple combination amlodipine/valsartan/ hydrochlorothiazide in patients with moderate-to-severe hypertension. Presented at: American Society of Hypertension, 24th Annual Scientific Meeting and Exposition; 6 - 9 May 2009; San Francisco, CA
    • American Society of Hypertension, 24th Annual Scientific Meeting and Exposition
    • Lacourciere, Y.1    Glazer, R.2    Crikelair, N.3
  • 66
    • 84925569599 scopus 로고    scopus 로고
    • Efficacy and safety of combination olmesartan medoxomil (OM) +amlodipine besylate (AML) hydrochlorothiazide (HCTZ) in patients with hypertension: The Trinity study [abstract PO-57]
    • Oparil S, Melino M, Fernandez V, et al. Efficacy and safety of combination olmesartan medoxomil (OM) +amlodipine besylate (AML) ?hydrochlorothiazide (HCTZ) in patients with hypertension: the Trinity study [abstract PO-57]. J Clin Hypertens 2010;12(Suppl 1):A42
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Oparil, S.1    Melino, M.2    Fernandez, V.3
  • 67
    • 77954809153 scopus 로고    scopus 로고
    • Safety and tolerability of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension [abstract PO-31]
    • Chrysant SG, Oparil S, Melino M, et al. Safety and tolerability of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) +hydrochlorothiazide (HCTZ) in patients with hypertension [abstract PO-31]. J Clin Hypertens 2010;12(Suppl 1):A31
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Chrysant, S.G.1    Oparil, S.2    Melino, M.3
  • 68
    • 77954800882 scopus 로고    scopus 로고
    • Twenty-four hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide [abstract PO-39]
    • Izzo J, Melino M, Fernandez V, et al. Twenty-four hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide [abstract PO-39]. J Clin Hypertens 2010;12(Suppl 1):A34-5
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Izzo, J.1    Melino, M.2    Fernandez, V.3
  • 69
    • 77954809153 scopus 로고    scopus 로고
    • Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension: Analysis by age and gender [abstract PO-30]
    • Chrysant SG, Melino M, Fernandez V, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) +hydrochlorothiazide (HCTZ) in patients with hypertension: analysis by age and gender [abstract PO-30]. J Clin Hypertens 2010;12(Suppl 1):A30-1
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Chrysant, S.G.1    Melino, M.2    Fernandez, V.3
  • 70
    • 77954770663 scopus 로고    scopus 로고
    • Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ)-The Trinity study: A subgroup analysis by race [abstract PO-50]
    • Littlejohn T, Toth P, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ)-the Trinity study: a subgroup analysis by race [abstract PO-50]. J Clin Hypertens 2010;12(Suppl 1):A39
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Littlejohn, T.1    Toth, P.2    Melino, M.3
  • 71
    • 77954794949 scopus 로고    scopus 로고
    • Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) based on severity of hypertension: The Trinity study [abstract PO-45]
    • Kereiakes D, Chrysant SG, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) +hydrochlorothiazide (HCTZ) based on severity of hypertension: the Trinity study [abstract PO-45]. J Clin Hypertens 2010;12(Suppl 1):A37
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Kereiakes, D.1    Chrysant, S.G.2    Melino, M.3
  • 72
    • 34250179723 scopus 로고    scopus 로고
    • Fixed-dose combinations improve medication compliance: A meta-analysis
    • Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719
    • (2007) Am J Med , vol.120 , pp. 713-719
    • Bangalore, S.1    Kamalakkannan, G.2    Parkar, S.3    Messerli, F.H.4
  • 73
    • 57649135136 scopus 로고    scopus 로고
    • Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy
    • Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. PT 2008;33:652-666
    • (2008) PT , vol.33 , pp. 652-666
    • Hess, G.1    Hill, J.2    Lau, H.3
  • 74
    • 0036189466 scopus 로고    scopus 로고
    • Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats
    • Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-462
    • (2002) Drugs , vol.62 , pp. 443-462
    • Sica, D.A.1
  • 75
    • 39749117949 scopus 로고    scopus 로고
    • Compliance with antihypertensive therapy in the elderly: A comparison of fixed-dose combination amlodipine/ benazepril versus component-based free-combination therapy
    • Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/ benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008;8:45-50
    • (2008) Am J Cardiovasc Drugs , vol.8 , pp. 45-50
    • Dickson, M.1    Plauschinat, C.A.2
  • 76
    • 1542440031 scopus 로고    scopus 로고
    • Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy
    • Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-332
    • (2003) Congest Heart Fail , vol.9 , pp. 324-332
    • Taylor, A.A.1    Shoheiber, O.2
  • 77
    • 0026329802 scopus 로고
    • Treating mild-to-moderate hypertension: A comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination
    • Graham RD. Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. J Hum Hypertens 1991;5(Suppl 2):59-60
    • (1991) J Hum Hypertens , vol.5 , Issue.SUPPL. 2 , pp. 59-60
    • Graham, R.D.1
  • 78
    • 36349021930 scopus 로고    scopus 로고
    • Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination
    • Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination. Curr Med Res Opin 2007;23:2877-2885
    • (2007) Curr Med Res Opin , vol.23 , pp. 2877-2885
    • Schweizer, J.1    Hilsmann, U.2    Neumann, G.3
  • 79
    • 74949125742 scopus 로고    scopus 로고
    • Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis
    • Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
    • (2010) Hypertension , vol.55 , pp. 399-407
    • Gupta, A.K.1    Arshad, S.2    Poulter, N.R.3
  • 80
    • 0036863587 scopus 로고    scopus 로고
    • Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    • Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
    • (2002) J Clin Hypertens (Greenwich) , vol.4 , pp. 393-404
    • Cushman, W.C.1    Ford, C.E.2    Cutler, J.A.3
  • 81
    • 15944409988 scopus 로고    scopus 로고
    • Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril
    • Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293:1595-1608
    • (2005) JAMA , vol.293 , pp. 1595-1608
    • Wright Jr., J.T.1    Dunn, J.K.2    Cutler, J.A.3
  • 82
    • 0345492460 scopus 로고    scopus 로고
    • A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial
    • Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816
    • (2003) JAMA , vol.290 , pp. 2805-2816
    • Pepine, C.J.1    Handberg, E.M.2    Cooper-Dehoff, R.M.3
  • 83
    • 0037851836 scopus 로고    scopus 로고
    • Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial
    • Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082
    • (2003) JAMA , vol.289 , pp. 2073-2082
    • Black, H.R.1    Elliott, W.J.2    Grandits, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.